CURRENT STUDIES

A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF
EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF
SEBORRHEIC DERMATITIS (DANDRUFF)

The treatment of recurrent seborrheic dermatitis demands a topical preparation that is safe for both short-term and chronic application. Extina (ketoconazole) Foam, 2% indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older, was approved for marketing in the United States in June 2007. This study is being conducted in order to obtain long-term safety data on the use of Extina (ketoconazole) Foam, 2% in the treatment of seborrheic dermatitis. We are currently recruiting male and female patients aged 12 and older who suffer from seborrheic dermatitis. Study visits will occur at baseline (day 1) and at weeks 4, 8, 16, 26, 39, and 52 (or early withdrawal). You will be compensated for your time.

For more information or to see if you may qualify call 561-372-SKIN or send an email to clinicalresearch@weissskininstitute.com